Gene:
AR
androgen receptor

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  DHTR; Kennedy disease; SBMA; testicular feminization
Alternate Symbols:  AIS; HUMARA; NR3C4; SMAX1
PharmGKB Accession Id: PA57

Details

Cytogenetic Location: chrX : q12 - q12
GP mRNA Boundary: chrX : 66763874 - 66950461
GP Gene Boundary: chrX : 66753874 - 66953461
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Curated Information ?

Publications related to AR: 9

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015. Xia Shu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England journal of medicine. 2014. Antonarakis Emmanuel S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature genetics. 2013. Lunardi Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PloS one. 2013. Yu Chia-Cheng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The modulating effect of the androgen receptor on craving in alcohol withdrawal of men is partially mediated by leptin. The pharmacogenomics journal. 2010. Lenz B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic approaches to outcome prediction in prostate cancer. Cancer. 2009. Febbo Phillip G. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. The Journal of clinical endocrinology and metabolism. 2004. Zitzmann Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Molecular and cellular endocrinology. 2004. Oelkers Wolfgang. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
All progestins are not created equal. Steroids. 2003. Stanczyk Frank Z. PubMed

LinkOuts

NCBI Gene:
367
OMIM:
176807
300068
300633
312300
313200
313700
UCSC Genome Browser:
NM_000044
RefSeq RNA:
NM_000044
NM_001011645
RefSeq Protein:
NP_000035
NP_001011645
RefSeq DNA:
NG_009014
NT_011669
UniProtKB:
ANDR_HUMAN (P10275)
Q9NUA2_HUMAN (Q9NUA2)
Ensembl:
ENSG00000169083
GenAtlas:
AR
GeneCard:
AR
MutDB:
AR
ALFRED:
LO000600G
HuGE:
AR
Comparative Toxicogenomics Database:
367
ModBase:
P10275
HumanCyc Gene:
HS09879
HGNC:
644

Common Searches